2Marcus R, Imrie K, Solal - Celigny P, et al. Phase III study of R - CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lyrephoma[ J ]. J Clin Oncol,2008,26 (28) :4579 - 4586.
3Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincrlstine, and prednlsone (CHOP) significantly improves the outcome for patients with advanced - stage follicular lymphoma compared with therapy with CHOP alone:results of a prospective randomized study of the German Low - Grade Lymphoma Study Group[J]. Blood,2005,106(12) :3725 -3732.
4Herald M, Haas A, Stuck S, et al. Rituximab added to first - line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma:an East German Study Group Hematology and Oncology Study[ J]. J Clio Oncol,2007,25 ( 15 ) : 1986 - 1992.
5Salles G,Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients:results of the GELA - GOELAMS FL2000 study [ J ]. Blood, 2008,4 : 153 - 189.
6Sehulz H, Bohlius JF, Trelle S, et al. lmmunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta - analysis [ J ]. J Nail Cancer Institute,2007,99(9) :706 -714.
7Sacchi S, Pozzi S, Marcheselli L, et al. Introduction of fituximab in front - line and salvage therapies has improved outcome of advanced - stage follicular lymphoma patients [ J ]. Cancer,2007,109 (10) :2077 - 2082.
8Buchegger F, Press OW, Delaloye AB, et al Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma [ J]. The Oncologist,2008,13 (6) :657 - 667.
9Fisher R, Kaminski M, Wahl R, et al. Tositumomab and Iodine- 131 Tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low grade and transformed non - Hodgkin's lymphomas [ J ]. J Clin Oncol, 2005,23 ( 30 ) : 7565 - 7573.
10Wiseman G, Witzig T. Yttrium -90 Ibritumomab Tiuxetan induces long - term durable responses in patients with relapsed or refracto- ry B - cell non - Hodgkin's lymphoma[ J]. Cance Biother Radiopharm,2005,20(2) :185 - 188.
